Radiomic Features Are Associated With EGFR Mutation Status in Lung Adenocarcinomas

Clinical Lung Cancer

Volumn 17, Issue 5, 2016, Pages 441-448.e6

  Liu, Ying ^a,b   Kim, Jongphil ^b   Balagurunathan, Yoganand ^b   Li, Qian ^a,b   Garcia, Alberto L ^b   Stringfield, Olya ^b   Ye, Zhaoxiang ^a   Gillies, Robert J ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Epidermal growth factor receptor; Logistic model; Peripheral lung adenocarcinoma; Tomography; X ray computed

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER GRADING; CLINICAL FEATURE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG LOBECTOMY; LUNG RESECTION; LUNG SEGMENTECTOMY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PHENOTYPE; PREDICTIVE VALUE; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SEX DIFFERENCE; SMOKING; THREE DIMENSIONAL IMAGING; TUMOR VOLUME; UNIVARIATE ANALYSIS; WEDGE RESECTION; ADENOCARCINOMA; ASIAN CONTINENTAL ANCESTRY GROUP; DIAGNOSTIC IMAGING; EPIDEMIOLOGY; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; PROCEDURES; STATISTICAL MODEL; VERY ELDERLY; X-RAY COMPUTED TOMOGRAPHY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PREDICTIVE VALUE OF TESTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SEX FACTORS; SMOKING; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84962614999     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2016.02.001     Document Type: Article

References (39)

1. 1 Halpenny, D.F., Riely, G.J., Hayes, S., et al. Are there imaging characteristics associated with lung adenocarcinomas harboring ALK rearrangements?. Lung Cancer 86 (2014), 190–194.
2. 2 Ganeshan, B., Panayiotou, E., Burnand, K., Dizdarevic, S., Miles, K., Tumour heterogeneity in non–small-cell lung carcinoma assessed by CT texture analysis: a potential marker of survival. Eur Radiol 22 (2012), 796–802.
3. 3 Mok, T.S., Wu, Y.L., Thongprasert, S., et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361 (2009), 947–957.
4. 4 Jackman, D.M., Miller, V.A., Cioffredi, L.A., et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non–small-cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 15 (2009), 5267–5273.
5. 5 Riely, G.J., Pao, W., Pham, D., et al. Clinical course of patients with non–small-cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 12 (2006), 839–844.
6. 6 Yang, J.C., Schuler, M.H., Yamamoto, N., et al. LUX-Lung 3: a randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. ASCO Annual Meeting, 2012 Abstract No: LBA7500.
7. 7 Maemondo, M., Inoue, A., Kobayashi, K., et al. Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR. N Engl J Med 362 (2010), 2380–2388.
8. 8 Kobayashi, K., Inoue, A., Maemondo, M., et al. First-line gefitinib versus first-line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in non–small-cell lung cancer (NSCLC) patients (pts) with EGFR mutations: a phase III study (002) by North East Japan Gefitinib Study Group. ASCO Annual Meeting, 2009 Abstract No: 8016.
9. 9 Mitsudomi, T., Morita, S., Yatabe, Y., et al. Gefitinib versus cisplatin plus docetaxel in patients with non–small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11 (2010), 121–128.
10. 10 Paez, J.G., Jänne, P.A., Lee, J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004), 1497–1500.
11. 11 Kosaka, T., Yatabe, Y., Endoh, H., Kuwano, H., Takahashi, T., Mitsudomi, T., Mutations of the epidermal growth factor receptor gene in lung cancer biological and clinical implications. Cancer Res 64 (2004), 8919–8923.
12. 12 Shahi, R.B., De Brakeleer, S., De Greve, J., Geers, C., In't Veld, P., Teugels, E., Detection of EGFR-TK domain-activating mutations in NSCLC with generic PCR-based methods. Appl Immunohistochem Mol Morphol 23 (2015), 163–171.
13. 13 Tomonaga, N., Nakamura, Y., Yamaguchi, H., et al. Analysis of intratumor heterogeneity of EGFR mutations in mixed type lung adenocarcinoma. Clin Lung Cancer 14 (2013), 521–526.
14. 14 Bai, H., Wang, Z., Wang, Y., et al. Detection and clinical significance of intratumoral EGFR mutational heterogeneity in Chinese patients with advanced non–small-cell lung cancer. PLoS One, 8, 2013, e54170.
15. 15 Taniguchi, K., Okami, J., Kodama, K., Higashiyama, M., Kato, K., Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci 99 (2008), 929–935.
16. 16 Querings, S., Altmüller, J., Ansén, S., et al. Benchmarking of mutation diagnostics in clinical lung cancer specimens. PLoS One, 6, 2011, e19601.
17. 17 Rizzo, S., Petrella, F., Buscarino, V., et al. CT radiogenomic characterization of EGFR, K-RAS, and ALK mutations in non–small -cell lung cancer. Eur Radiol 26 (2016), 32–42.
18. 18 Zhou, J.Y., Zheng, J., Yu, Z.F., et al. Comparative analysis of clinicoradiologic characteristics of lung adenocarcinomas with ALK rearrangements or EGFR mutations. Eur Radiol 25 (2015), 1257–1266.
19. 19 Lee, Y., Lee, H.J., Kim, Y.T., et al. Imaging characteristics of stage I non–small-cell lung cancer on CT and FDG-PET: relationship with epidermal growth factor receptor protein expression status and survival. Korean J Radiol 14 (2013), 375–383.
20. 20 Lee, H.J., Kim, Y.T., Kang, C.H., et al. Epidermal growth factor receptor mutation in lung adenocarcinomas: relationship with CT characteristics and histologic subtypes. Radiology 268 (2013), 254–264.
21. 21 Kumar, V., Gu, Y., Basu, S., et al. Radiomics: the process and the challenges. Magn Reson Imaging 30 (2012), 1234–1248.
22. 22 Parmar, C., Velazquez, E.R., Leijenaar, R., et al. Robust radiomics feature quantification using semiautomatic volumetric segmentation. PLoS One, 9, 2014, e102107.
23. 23 Mattonen, S.A., Palma, D.A., Haasbeek, C.J., Senan, S., Ward, A.D., Early prediction of tumor recurrence based on CT texture changes after stereotactic ablative radiotherapy (SABR) for lung cancer. Med Phys, 41, 2014, 033502.
24. 24 Weiss, G.J., Ganeshan, B., Miles, K.A., et al. Noninvasive image texture analysis differentiates K-ras mutation from pan-wildtype NSCLC and is prognostic. PLoS One, 9, 2014, e100244.
25. 25 Ravanelli, M., Farina, D., Morassi, M., et al. Texture analysis of advanced non–small-cell lung cancer (NSCLC) on contrast-enhanced computed tomography: prediction of the response to the first-line chemotherapy. Eur Radiol 23 (2013), 3450–3455.
26. 26 Coroller, T.P., Grossmann, P., Hou, Y., et al. CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma. Radiother Oncol 114 (2015), 345–350.
27. 27 Edge, S.B., Compton, C.C., The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17 (2010), 1471–1474.
28. 28 Travis, W.D., Brambilla, E., Noguchi, M., et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc 8 (2011), 381–385.
29. 29 Locatelli-Sanchez, M., Couraud, S., Arpin, D., Riou, R., Bringuier, P.P., Souquet, P.J., Routine EGFR molecular analysis in non–small-cell lung cancer patients is feasible: exons 18–21 sequencing results of 753 patients and subsequent clinical outcomes. Lung 191 (2013), 491–499.
30. 30 Balagurunathan, Y., Kumar, V., Gu, Y., et al. Test-retest reproducibility analysis of lung CT image features. J Digit Imaging 27 (2014), 805–823.
31. 31 Gu, Y., Kumar, V., Hall, L.O., et al. Automated delineation of lung tumors from CT images using a single-click ensemble segmentation approach. Pattern Recognit 46 (2013), 692–702.
32. 32 Velazquez, E.R., Aerts, H.J., Gu, Y., et al. A semiautomatic CT-based ensemble segmentation of lung tumors: Comparison with oncologists’ delineations and with the surgical specimen. Radiother Oncol 105 (2012), 167–173.
33. 33 Balagurunathan, Y., Gu, Y., Wang, H., et al. Reproducibility and prognosis of quantitative features extracted from CT images. Transl Oncol 7 (2014), 72–87.
34. 34 Randen, T., Husøy, J.H., Filtering for texture classification: a comparative study. IEEE Trans Pattern Anal Mach Intell 21 (1999), 291–310.
35. 35 da Cunha Santos, G., Shepherd, F.A., Tsao, M.S., EGFR mutations and lung cancer. Annu Rev Pathol 6 (2011), 49–69.
36. 36 Liu, W.S., Zhao, L.J., Pang, Q.S., Yuan, Z.Y., Li, B., Wang, P., Prognostic value of epidermal growth factor receptor mutations in resected lung adenocarcinomas. Med Oncol, 31, 2014, 771.
37. 37 Ozkan, E., West, A., Dedelow, J.A., et al. CT gray-level texture analysis as a quantitative imaging biomarker of epidermal growth factor receptor mutation status in adenocarcinoma of the lung. AJR Am J Roentgenol 205 (2015), 1016–1025.
38. 38 Zhao, B., James, L.P., Moskowitz, C.S., et al. Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non–small-cell lung cancer. Radiology 252 (2009), 263–272.
39. 39 Hsu, J.S., Huang, M.S., Chen, C.Y., et al. Correlation between EGFR mutation status and computed tomography features in patients with advanced pulmonary adenocarcinoma. J Thorac Imaging 29 (2014), 357–363.